Next week we’ll be at ASGCT #ASGCT2025 sharing in vivo gene editing preclinical data. Learn more: bit.ly/3REdwK0 #invivogeneediting #geneediting #Biotechnology

On this #InternationalThalassaemiaDay we stand together with the community in solidarity to continue our work ensuring that all individuals with thalassemia are heard, valued and prioritized. #WeAre1 #PatientsFirst #ITD2025 #InternationalThalassemiaDay

#News: Editas Medicine announces U.S. Court of Appeals for the Federal Circuit remands CRISPR patent interference to Patent Trial and Appeal Board. Read the press release for details: bit.ly/4deokZ5 #patent #geneediting #crispr #biotechnology

Today, we announced business updates and financial results for the first quarter 2025. Read the full press release for details: bit.ly/4iZp5Xc #invivogeneediting #geneediting #Biotechnology

#News: Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting. Read the release for more details: bit.ly/4dahmUY #ASGCT2025 #invivogeneediting #geneediting #Biotechnology

Yesterday, we reported business updates and financial results for the first quarter 2025. Learn more: bit.ly/4iZp5Xc #invivogeneediting #geneediting #Biotechnology

Today, we’ll be presenting at the Bank of America Global Healthcare Conference at 5:15 p.m. PT (8:15 p.m. ET). Listen live: bit.ly/3EZIGsD #invivogeneediting #geneediting #Biotechnology #healthcare

Attending #ASGCT2025? Stop by to see our posters, AMA245 and AMA420 in the Tuesday Poster Reception Hall 12 from 6:00 p.m.– 7:30 p.m. CT today. You can also visit our website to view the posters: bit.ly/3wR3jht #invivogeneediting #geneediting #Biotechnology

Listen live to today's Editas presentation at the Bank of America Global Healthcare Conference at 5:15 p.m. PT (8:15 p.m. ET). Listen live: bit.ly/3EZIGsD #invivogeneediting #geneediting #Biotechnology #healthcare

#News: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting. Read the press release for details: bit.ly/4mhHnGc #ASGCT2025 #invivogeneediting

#News: Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data European Hematology Association 2025 Congress in June. Read the press release for details: bit.ly/4kjOQmn European Hematology Association #EHA2025

Good morning from #ASGCT2025! Today we are presenting pre-clinical data to support our development of transformative in vivo gene editing medicines. For presentation information, visit bit.ly/3REdwK0 #invivogeneediting #geneediting #Biotechnology

Join us today in Room 265-268, from 1:30-1:45 p.m. for our oral presentation, “In Vivo Delivery of HBG1/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-Human Primate with Lipid Nanoparticle”, at #ASGCT2025. #invivogeneediting #geneediting #Biotechnology

Attending #ASGCT2025? Check out our posters AMA640 and AMA351 featured during the Wednesday Poster Reception from 5:30 p.m. – 7:00 p.m. CT in Hall 12 or you can view them online here: bit.ly/3wR3jht #invivogeneediting #geneediting #Biotechnology

Next week we’ll be participating in the #TIDESUSA 2025 Meeting. Learn more: bit.ly/3Eni0g2 #invivogeneediting #geneediting #Biotechnology

In her PharmaVoice interview, CFO Amy Parison shares her perspective on joining Editas as we focus on in vivo gene editing. Her approach reflects the clarity and discipline guiding our next chapter. #GeneEditing #InVivoGeneEditing Full interview: bit.ly/3SGKRnU

We’re at the #TIDESUSA 2025 Meeting. Over the next week, we’ll be presenting preclinical data to support our development of transformative in vivo gene editing medicines. For presentation information, visit the TIDES agenda: bit.ly/3Eni0g2 #invivogeneediting #geneediting

#News: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at #EHA2025: Read the press release at bit.ly/3ZupBps #hematology #invivogeneediting

#News: Editas Medicine Announces Second Quarter 2025 Results and Business Updates. Read the press release for details: [ bit.ly/4mhovH0 ] #invivogeneediting #geneediting #Biotechnology

#News: Editas Medicine to Participate in Upcoming Investor Conferences. For more details, read the full press release here: [bit.ly/4g6ayt5] #invivogeneediting #biotechnology #healthcare